CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Analysis of the safety profile of the TNF-alpha antibody infliximab based on the pooled data of 3 German post-marketing surveillance studies with 1,075 patients suffering from rheumatoid arthritis or Crohn's disease
DOI 10.1055/s-2004-831462
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJR Kalden, HP Tony, C Antoni, C Rauch
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2004
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
We planned to evaluate the safety profile of the TNF-alpha antagonist infliximab (IFX) in a large population of patients with rheumatoid arthritis (RA) or Crohn's disease (CD) treated with IFX under routine conditions in the post-marketing phase. Therefore, we pooled the data of 3 independently performed post-marketing surveillance studies (PMSs, 2 studies with 309 and 107 CD patients, respectively, and 1 study with…
Zitieren
Zitierempfehlung
JR Kalden, HP Tony, C Antoni, C Rauch (2004) Analysis of the safety profile of the TNF-alpha antibody infliximab based on the pooled data of 3 German post-marketing surveillance studies with 1,075 patients suffering from rheumatoid arthritis or Crohn's disease. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-2004-831462
Mit CareLit weiterarbeiten